288 related articles for article (PubMed ID: 23841999)
1. Signal transduction inhibitors in treatment of myelodysplastic syndromes.
Bachegowda L; Gligich O; Mantzaris I; Schinke C; Wyville D; Carrillo T; Braunschweig I; Steidl U; Verma A
J Hematol Oncol; 2013 Jul; 6():50. PubMed ID: 23841999
[TBL] [Abstract][Full Text] [Related]
2. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
Zhou L; McMahon C; Bhagat T; Alencar C; Yu Y; Fazzari M; Sohal D; Heuck C; Gundabolu K; Ng C; Mo Y; Shen W; Wickrema A; Kong G; Friedman E; Sokol L; Mantzaris I; Pellagatti A; Boultwood J; Platanias LC; Steidl U; Yan L; Yingling JM; Lahn MM; List A; Bitzer M; Verma A
Cancer Res; 2011 Feb; 71(3):955-63. PubMed ID: 21189329
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.
Bewersdorf JP; Zeidan AM
Leukemia; 2019 Jun; 33(6):1303-1312. PubMed ID: 30962581
[TBL] [Abstract][Full Text] [Related]
5. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.
Xu F; He Q; Li X; Chang CK; Wu LY; Zhang Z; Liu L; Shi WH; Zhu Y; Zhao YS; Gu SC; Fei CM; Guo J; Wu D; Zhou L
Sci Rep; 2014 Dec; 4():7310. PubMed ID: 25472472
[TBL] [Abstract][Full Text] [Related]
6. Cytokine targets in the treatment of myelodysplastic syndromes.
Verma A; List AF
Curr Hematol Rep; 2005 Nov; 4(6):429-35. PubMed ID: 16232378
[TBL] [Abstract][Full Text] [Related]
7. p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.
Zhou L; Opalinska J; Verma A
Cell Cycle; 2007 Mar; 6(5):534-7. PubMed ID: 17351344
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Zhou L; Nguyen AN; Sohal D; Ying Ma J; Pahanish P; Gundabolu K; Hayman J; Chubak A; Mo Y; Bhagat TD; Das B; Kapoun AM; Navas TA; Parmar S; Kambhampati S; Pellagatti A; Braunchweig I; Zhang Y; Wickrema A; Medicherla S; Boultwood J; Platanias LC; Higgins LS; List AF; Bitzer M; Verma A
Blood; 2008 Oct; 112(8):3434-43. PubMed ID: 18474728
[TBL] [Abstract][Full Text] [Related]
9. Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Bachegowda L; Morrone K; Winski SL; Mantzaris I; Bartenstein M; Ramachandra N; Giricz O; Sukrithan V; Nwankwo G; Shahnaz S; Bhagat T; Bhattacharyya S; Assal A; Shastri A; Gordon-Mitchell S; Pellagatti A; Boultwood J; Schinke C; Yu Y; Guha C; Rizzi J; Garrus J; Brown S; Wollenberg L; Hogeland G; Wright D; Munson M; Rodriguez M; Gross S; Chantry D; Zou Y; Platanias L; Burgess LE; Pradhan K; Steidl U; Verma A
Cancer Res; 2016 Aug; 76(16):4841-4849. PubMed ID: 27287719
[TBL] [Abstract][Full Text] [Related]
10. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes.
Peng H; Wen J; Zhang L; Li H; Chang CC; Zu Y; Zhou X
Mol Biosyst; 2012 Apr; 8(4):1366-74. PubMed ID: 22327869
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
12. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
[TBL] [Abstract][Full Text] [Related]
13. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.
Schinke C; Giricz O; Li W; Shastri A; Gordon S; Barreyro L; Bhagat T; Bhattacharyya S; Ramachandra N; Bartenstein M; Pellagatti A; Boultwood J; Wickrema A; Yu Y; Will B; Wei S; Steidl U; Verma A
Blood; 2015 May; 125(20):3144-52. PubMed ID: 25810490
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Navas T; Zhou L; Estes M; Haghnazari E; Nguyen AN; Mo Y; Pahanish P; Mohindru M; Cao T; Higgins LS; Platanias LC; List A; Verma A; Bhagat T; Gajavelli S; Kambhampati S
Leuk Lymphoma; 2008 Oct; 49(10):1963-75. PubMed ID: 18949619
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action.
Lainey E; Thépot S; Bouteloup C; Sébert M; Adès L; Tailler M; Gardin C; de Botton S; Baruchel A; Fenaux P; Kroemer G; Boehrer S
Biochem Pharmacol; 2011 Nov; 82(10):1457-66. PubMed ID: 21664897
[TBL] [Abstract][Full Text] [Related]
16. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
17. Targeting inflammation in lower-risk MDS.
Gonzalez-Lugo JD; Verma A
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):382-387. PubMed ID: 36485128
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
Navas TA; Mohindru M; Estes M; Ma JY; Sokol L; Pahanish P; Parmar S; Haghnazari E; Zhou L; Collins R; Kerr I; Nguyen AN; Xu Y; Platanias LC; List AA; Higgins LS; Verma A
Blood; 2006 Dec; 108(13):4170-7. PubMed ID: 16940419
[TBL] [Abstract][Full Text] [Related]
19. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.
Katsoulidis E; Li Y; Yoon P; Sassano A; Altman J; Kannan-Thulasiraman P; Balasubramanian L; Parmar S; Varga J; Tallman MS; Verma A; Platanias LC
Cancer Res; 2005 Oct; 65(19):9029-37. PubMed ID: 16204077
[TBL] [Abstract][Full Text] [Related]
20. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling.
Bhagat TD; Zhou L; Sokol L; Kessel R; Caceres G; Gundabolu K; Tamari R; Gordon S; Mantzaris I; Jodlowski T; Yu Y; Jing X; Polineni R; Bhatia K; Pellagatti A; Boultwood J; Kambhampati S; Steidl U; Stein C; Ju W; Liu G; Kenny P; List A; Bitzer M; Verma A
Blood; 2013 Apr; 121(15):2875-81. PubMed ID: 23390194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]